Latest:
Dr. Gisslinger on EFS Rates With Ropeginterferon Alfa-2b in Polycythemia Vera
Heinz Gisslinger, MD, discusses the 6-year event-free survival data from the phase 3 PROUD-PV and CONTI-PV trials.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Heinz-Josef Lenz, MD
Heinz-Josef Lenz, MD, is a professor of medicine and cancer biology, and the J. Terrence Lanni Chair in Gastrointestinal Cancer Research at the Keck School of Medicine of the University of the University of Southern California (USC); as well as the co-director of the USC Center for Molecular Pathway and Drug Discovery and the co-director of the USC Norris Center for Cancer Drug Development
Latest:
Dr Lenz on the FDA Approval of Nivolumab Plus Ipilimumab for dMMR/MSI-H mCRC
Heinz-Josef Lenz, MD, discusses data from the CheckMate 8HW trial that led to the FDA approval of nivolumab plus ipilimumab for dMMR/MSI-H metastatic CRC.
Helen Foley, MSN, AOCNS®
Latest:
Preparing Nurses for Advanced Practice in Oncology and Palliative Care
Barbara Daly, PhD, RN, FAAN, and Helen Foley, MSN, AOCNS®, offer highlights of their institution's oncology and palliative care program, which successfully prepares graduates to assume advanced practice roles in these important areas.
Helena A. Yu, MD
Latest:
The Future of Tumor Agnostic Therapies in EGFRm m NSCLC
Experts discuss the expanding treatment landscape for EGFR-mutated non–small cell lung cancer (NSCLC), highlighting emerging strategies beyond tyrosine kinase inhibitors (TKIs)—including novel immunotherapy combinations and antibody-drug conjugates (ADCs)—with particular interest in bispecific antibodies and TROP2-directed ADCs that may offer new options for patients progressing on targeted therapy, despite ongoing challenges in translating immune-based approaches into consistent survival gains.
Henry M. Kuerer, MD, PhD, FACS, CMQ
Henry M. Kuerer, MD, is a Professor and Executive Director Breast Programs, MD Anderson Cancer Network, Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Latest:
Dr Kuerer on the Safety, Feasibility of Omitting Surgery in Select Patients With HER2+, Triple-Negative Breast Cancer
Henry M. Kuerer, MD, PhD, FACS, CMQ, discusses the feasibility of eliminating surgery in select patients with a pCR after neoadjuvant therapy for breast cancer.
Herbert A. Eradat, MD
Latest:
Dr. Eradat on Rituximab Biosimilar in CD20+ B-Cell Non-Hodgkin Lymphoma and CLL
Herbert A. Eradat, MD, discusses the implications of the FDA approval of rituximab-pvvr (Ruxience), a biosimilar to rituximab (Rituxan) in patients with CD20-positive B-cell Non-Hodgkin lymphoma and chronic lymphocytic leukemia.